MNPR — Monopar Therapeutics

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1645469 ·
Last close
$71.06
Market Cap
$481.56M
52W High
$124.82
52W Low
$50.07
ADV30
149,339
Next earnings
2026-11-12
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,467,845 -6,196,475 130,249,286 52,634,362 3,181,854
Jun 2026 0 — -6,644,663 -5,313,300 134,978,829 52,757,766 4,123,859
Mar 2026 0 — -5,225,253 -3,893,050 137,983,725 52,544,263 2,589,313
Dec 2025 0 — -6,155,228 -5,200,795 140,717,709 61,833,552 2,890,156

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-16,266,103
Investing CF
$-58,194,193
Financing CF
$-646,040
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.28
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-104,912,355
Inventory
—
Receivables
—
ST Investments
$76,813,334
EBIT TTM
$-25,492,989
Pretax Income TTM
$-20,603,620
Interest Exp TTM
—
Analysts
12

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -16,704,415 -13,716,894 140,717,709 2,890,156 137,827,553 -12,201,291
Dec 2024 0 -16,161,721 -15,586,419 60,291,071 5,254,300 55,036,771 -6,404,139
Dec 2023 0 -8,831,235 -8,402,196 7,345,159 1,757,393 5,587,766 -7,858,293
Dec 2022 0 -10,536,877 -10,515,638 13,226,954 3,137,302 10,089,652 -7,228,559

TTM Snapshot

Revenues TTM
$4,241,315
NetIncome TTM
$-17,844,746
OpCashFlow TTM
—
Assets (Latest)
$134,978,829
Forward EPS
$-2.97

Peers — same industry

TickerNameMarket CapLastDaily %
BLSM BlossomHill Therapeutics, Inc. $480.91M $15.13 —
IMMP IMMUTEP Ltd $480.43M $3.26 —
NGNE Neurogene Inc. $478.19M $23.10 —
GYRE GYRE THERAPEUTICS, INC. $488.23M $4.56 —
CAPR CAPRICOR THERAPEUTICS, INC. $488.98M $8.41 —

News headlines (Yahoo Finance, 1h cache)

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 13:00 · Yahoo
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
2026-11-09 13:00 · Yahoo
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
2026-11-02 13:00 · Yahoo
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-12 13:30 · Yahoo
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
2026-07-22 12:00 · Yahoo
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
2026-07-20 12:00 · Yahoo
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
2026-06-26 20:05 · Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
2026-05-03 13:26 · Yahoo
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
2026-06-01 11:00 · Yahoo
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 18:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.